Last reviewed · How we verify
Phase 2; High Dose MYOBLOC — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Phase 2; High Dose MYOBLOC (Phase 2; High Dose MYOBLOC) — Supernus Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Phase 2; High Dose MYOBLOC TARGET | Phase 2; High Dose MYOBLOC | Supernus Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Phase 2; High Dose MYOBLOC CI watch — RSS
- Phase 2; High Dose MYOBLOC CI watch — Atom
- Phase 2; High Dose MYOBLOC CI watch — JSON
- Phase 2; High Dose MYOBLOC alone — RSS
Cite this brief
Drug Landscape (2026). Phase 2; High Dose MYOBLOC — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-2-high-dose-myobloc. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab